Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies

Caruba Thibaut, Katsahian Sandrine, Schramm Catherine, Charles Nelson Anaïs, Durieux Pierre, Bégué Dominique, Juillière Yves, Dubourg Olivier, Danchin Nicolas, Sabatier Brigitte

INTRODUCTION AND OBJECTIVES: Numerous studies have assessed cost-effectiveness of different treatment modalities for stable angina. Direct comparisons, however, are uncommon. We therefore set out to compare the efficacy and mean cost per patient after 1 and 3 years of follow-up, of the following treatments as assessed in randomized controlled trials (RCT): medical therapy (MT), percutaneous coronary intervention (PCI) without stent (PTCA), with bare-metal stent (BMS), with drug-eluting stent (DES), and elective coronary artery bypass graft (CABG). METHODS: RCT comparing at least two of the five treatments and reporting clinical and cost data were identified by a systematic search. Clinical end-points were mortality and myocardial infarction (MI). The costs described in the different trials were standardized and expressed in US $ 2008, based on purchasing power parity. A network meta-analysis was used to compare costs. RESULTS: Fifteen RCT were selected. Mortality and MI rates were similar in the five treatment groups both for 1-year and 3-year follow-up. Weighted cost per patient however differed markedly for the five treatment modalities, at both one year and three years (P<0.0001). MT was the least expensive treatment modality: US $3069 and 13 864 after one and three years of follow-up, while CABG was the most costly: US $27 003 and 28 670 after one and three years. PCI, whether with plain balloon, BMS or DES came in between, but was closer to the costs of CABG. CONCLUSIONS: Appreciable savings in health expenditures can be achieved by using MT in the management of patients with stable angina.

2014. PLoS ONE; 9(6):e98371
Link to pubmed

comments powered by Disqus